New methods to deliver microRNA treatments for liver disease caused by alcohol.
Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease
This study is looking at new ways to deliver special treatments using tiny particles that can help improve liver health for people dealing with alcohol-related liver disease, with the hope of stopping or even reversing liver damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10676945 on NIH RePORTER |
What this research studies
This research focuses on developing innovative delivery methods for microRNA treatments aimed at addressing alcohol-associated liver disease (AALD). It explores the use of self-assembled nanoparticles to deliver specific microRNAs that can target and modulate multiple pathways involved in liver fibrosis and inflammation. By targeting key cellular components in the liver, the research aims to improve treatment efficacy and reduce liver damage. Patients may benefit from a novel therapeutic approach that could potentially reverse or halt the progression of liver disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol-associated liver disease, including those with fatty liver disease, alcoholic hepatitis, or fibrosis.
Not a fit: Patients with liver disease not associated with alcohol consumption or those with end-stage liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from alcohol-associated liver disease.
How similar studies have performed: While the use of microRNA therapies is a relatively novel approach, preliminary studies have shown promise in targeting liver diseases, indicating potential for success in this area.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Oupicky, David — University of Nebraska Medical Center
- Study coordinator: Oupicky, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.